Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384199314> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4384199314 abstract "Acute myeloid leukemia (AML) is a heterogeneous disease with variable genetic features and clinical outcomes. The main curative option for AML remains intensive chemotherapy and allogeneic hematopoietic stem cell transplant (HSCT) in selected patients. However, with a median age at diagnosis of 67 years old and frequent comorbidities, a large proportion of patients diagnosed with AML are not eligible for intensive chemotherapy. Until recently, the only treatments available for patients with AML ineligible for intensive chemotherapy were single-agent hypomethylating agents (HMAs) such as azacitidine and decitabine, or low-dose cytarabine (LDAC). In older patients with AML, these treatments have been reported to improve outcomes over best supportive care (BSC) alone. However, in clinical studies the expected median overall survival (OS) remained less than 12 months. Fortunately, our increasing knowledge of AML biology has accelerated the development of novel targeted drugs for AML. Among these, the anti-apoptotic protein B-cell lymphoma 2 (BCL2) inhibitor venetoclax has completely changed the therapeutic landscape of AML, especially for patients who are ineligible for intensive chemotherapy. Venetoclax is approved by Health Canada for use in combination with azacitidine or LDAC for the treatment of newly diagnosed untreated AML in patients who are 75 years or older or have comorbidities precluding the use of intensive chemotherapy. This approval is based on the two pivotal randomized, Phase 3 trials VIALE-A (azacitidine plus venetoclax) and VIALE-C (cytarabine plus venetoclax). Although seemingly easier to administer than intensive chemotherapy, venetoclax-based regimens are not as “non-intensive” as they are sometimes considered to be. They require the implementation of specific precautionary measures and monitoring to avoid excessive toxicity and optimize patients’ outcomes. We will review here practical points to safely administer venetoclax-based regimens to patients with AML who are ineligible for intensive chemotherapy." @default.
- W4384199314 created "2023-07-14" @default.
- W4384199314 creator A5043364502 @default.
- W4384199314 date "2023-03-01" @default.
- W4384199314 modified "2023-10-04" @default.
- W4384199314 title "Venetoclax-based lower-intensity regimens for acute myeloid leukemia" @default.
- W4384199314 cites W1600365609 @default.
- W4384199314 cites W2068556430 @default.
- W4384199314 cites W2106084333 @default.
- W4384199314 cites W2111724321 @default.
- W4384199314 cites W2144395887 @default.
- W4384199314 cites W2470291098 @default.
- W4384199314 cites W2583145471 @default.
- W4384199314 cites W2890837116 @default.
- W4384199314 cites W2992053862 @default.
- W4384199314 cites W2994138807 @default.
- W4384199314 cites W3007376421 @default.
- W4384199314 cites W3013447738 @default.
- W4384199314 cites W3037482073 @default.
- W4384199314 cites W3048827006 @default.
- W4384199314 cites W3213427430 @default.
- W4384199314 cites W4284884567 @default.
- W4384199314 doi "https://doi.org/10.58931/cht.2023.2125" @default.
- W4384199314 hasPublicationYear "2023" @default.
- W4384199314 type Work @default.
- W4384199314 citedByCount "0" @default.
- W4384199314 crossrefType "journal-article" @default.
- W4384199314 hasAuthorship W4384199314A5043364502 @default.
- W4384199314 hasBestOaLocation W43841993141 @default.
- W4384199314 hasConcept C104317684 @default.
- W4384199314 hasConcept C126322002 @default.
- W4384199314 hasConcept C143998085 @default.
- W4384199314 hasConcept C150194340 @default.
- W4384199314 hasConcept C185592680 @default.
- W4384199314 hasConcept C190727270 @default.
- W4384199314 hasConcept C2776239401 @default.
- W4384199314 hasConcept C2776694085 @default.
- W4384199314 hasConcept C2777938653 @default.
- W4384199314 hasConcept C2778041864 @default.
- W4384199314 hasConcept C2778461978 @default.
- W4384199314 hasConcept C2778729363 @default.
- W4384199314 hasConcept C2779675984 @default.
- W4384199314 hasConcept C2780235182 @default.
- W4384199314 hasConcept C55493867 @default.
- W4384199314 hasConcept C71924100 @default.
- W4384199314 hasConceptScore W4384199314C104317684 @default.
- W4384199314 hasConceptScore W4384199314C126322002 @default.
- W4384199314 hasConceptScore W4384199314C143998085 @default.
- W4384199314 hasConceptScore W4384199314C150194340 @default.
- W4384199314 hasConceptScore W4384199314C185592680 @default.
- W4384199314 hasConceptScore W4384199314C190727270 @default.
- W4384199314 hasConceptScore W4384199314C2776239401 @default.
- W4384199314 hasConceptScore W4384199314C2776694085 @default.
- W4384199314 hasConceptScore W4384199314C2777938653 @default.
- W4384199314 hasConceptScore W4384199314C2778041864 @default.
- W4384199314 hasConceptScore W4384199314C2778461978 @default.
- W4384199314 hasConceptScore W4384199314C2778729363 @default.
- W4384199314 hasConceptScore W4384199314C2779675984 @default.
- W4384199314 hasConceptScore W4384199314C2780235182 @default.
- W4384199314 hasConceptScore W4384199314C55493867 @default.
- W4384199314 hasConceptScore W4384199314C71924100 @default.
- W4384199314 hasLocation W43841993141 @default.
- W4384199314 hasOpenAccess W4384199314 @default.
- W4384199314 hasPrimaryLocation W43841993141 @default.
- W4384199314 hasRelatedWork W2889423049 @default.
- W4384199314 hasRelatedWork W3081879830 @default.
- W4384199314 hasRelatedWork W3174529851 @default.
- W4384199314 hasRelatedWork W3215910920 @default.
- W4384199314 hasRelatedWork W4206245401 @default.
- W4384199314 hasRelatedWork W4220981828 @default.
- W4384199314 hasRelatedWork W4224925603 @default.
- W4384199314 hasRelatedWork W4283314520 @default.
- W4384199314 hasRelatedWork W4312049268 @default.
- W4384199314 hasRelatedWork W4362454943 @default.
- W4384199314 isParatext "false" @default.
- W4384199314 isRetracted "false" @default.
- W4384199314 workType "article" @default.